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Abstract: Little is known about the mechanism of prediabetes-induced cardiac dysfunction. Therefore,
we aimed to explore key molecular changes with transcriptomic and bioinformatics approaches in
a prediabetes model showing heart failure with preserved ejection fraction phenotype. To induce
prediabetes, Long-Evans rats were fed a high-fat diet for 21 weeks and treated with a single low-dose
streptozotocin at week 4. Small RNA-sequencing, in silico microRNA (miRNA)-mRNA target
prediction, Gene Ontology analysis, and target validation with qRT-PCR were performed in left
ventricle samples. From the miRBase-annotated 752 mature miRNA sequences expression of 356
miRNAs was detectable. We identified two upregulated and three downregulated miRNAs in the
prediabetic group. We predicted 445 mRNA targets of the five differentially expressed miRNAs and
selected 11 mRNAs targeted by three differentially expressed miRNAs, out of which five mRNAs were
selected for validation. Out of these five targets, downregulation of three mRNAs i.e., Juxtaposed
with another zinc finger protein 1 (Jazf1); RAP2C, member of RAS oncogene family (Rap2c); and Zinc
finger with KRAB and SCAN domains 1 (Zkscan1) were validated. This is the first demonstration that
prediabetes alters cardiac miRNA expression profile. Predicted targets of differentially expressed
miRNAs include Jazf1, Zkscan1, and Rap2c mRNAs. These transcriptomic changes may contribute to
the diastolic dysfunction and may serve as drug targets.
Keywords: prediabetes; heart; network analysis; microRNA; diastolic dysfunction; comorbidities
1. Introduction
Type 2 diabetes mellitus (T2DM) is a common metabolic disorder, the global prevalence of which
has been increasing over recent decades [1–3]. It is well established that T2DM, a common risk factor
of cardiovascular diseases, increases the prevalence and mortality of acute myocardial infarction and
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heart failure [2,4]. Prediabetes, a precursor state of diabetes mellitus, characterized by impaired glucose
tolerance, impaired fasting glucose and raised hemoglobin A1c, increases cardiovascular risk [5].
Early diagnosis of the prediabetic state is important since proper interventions may slow or prevent
the progress to diabetes mellitus and reduce the risk of diabetic complications [3,6,7].
It has been reported that prediabetes could induce heart failure with preserved ejection fraction
(HFpEF) characterized by diastolic dysfunction in rats [8] and in patients [9,10] where atrial mechanical
dysfunction may also be detected. Several molecular mechanisms are shown to contribute to diastolic
dysfunction, such as cardiac mitochondrial disturbances, cardiac lipid accumulation, decreased
β-myosin heavy chain (β-MHC) expression, and decreased Sarcoplasmic/endoplasmic reticulum
calcium ATPase 2a (SERCA2a) activity [8,11–13]. Nevertheless, no effective therapy for the prevention or
treatment of HFpEF due to prediabetes is available [8–10], plausibly due to our imperfect understanding
of the underlying cardiac molecular alterations.
A relatively novel and efficient approach to uncover non-canonical players in pathologies is
the use of unbiased microRNA (miRNA)-based transcriptomics methods followed by in silico target
prediction by molecular network analysis and experimental target validation [14,15] according to
the recommendation of the European Society of Cardiology Working Group on Cellular Biology of
the Heart [15]. Although some miRNAs have been previously shown to prevent complications of
diabetes mellitus such as cardiomyopathy and nephropathy [16], there are no data in the literature
about miRNA-mRNA network changes in the heart due to prediabetes obtained by unbiased methods.
Therefore, the aim of the present study was to explore key molecular changes in a rat model of
prediabetes showing HFpEF phenotype with an unbiased approach using small RNA-sequencing,
followed by target prediction by molecular network analysis and experimental validation of the
predicted molecular targets.
2. Results
2.1. Differentially Expressed miRNAs
Using small RNA-sequencing analysis, the expression of 356 different miRNAs was detectable in rat
left ventricle samples out of the 752 mature miRNA sequences available in the reference annotation [17].
As compared to the control group, rno-miR-141-3p and rno-miR-200c-3p were significantly upregulated
while rno-miR-200a-3p, rno-miR-208b-3p and rno-miR-293-5p showed significant downregulation in
the prediabetic group (Table 1).
Table 1. Differentially expressed miRNAs from left ventricular samples. LogFC, base 2 logarithm of the
fold change; p-values were calculated by the edgeR software package using likelihood ratio tests after
applying generalized linear models (GLM) to estimate dispersions. FDR, false-discovery rate (adjusted
p-value according to Benjamini and Hochberg).
miRNA Name logFC p-Value FDR Expression Change
rno-miR-141-3p 2.49 < 0.001 < 0.001 up
rno-miR-200a-3p −1.41 < 0.001 0.037 down
rno-miR-200c-3p 2.51 < 0.001 < 0.001 up
rno-miR-208b-3p −1.56 < 0.001 0.012 down
rno-miR-293-5p −1.99 0.001 0.045 down
2.2. In Silico miRNA Target Prediction and Network Analysis
By in silico miRNA-mRNA target analysis, 445 mRNAs were predicted to be regulated by the five
significantly differentially expressed miRNAs. The full list of targets with the interacting miRNAs
is shown in Table S1. In the miRNA–target interaction network (Figure 1), the maximal target node
degree, i.e., the highest number of interacting miRNAs for one target, was three. Eleven mRNA
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targets could be characterized by this maximal degree, therefore, these targets were considered to be
target hubs with a high probability to be differentially expressed as a result of the miRNA-mediated
regulation. All of these 11 targets had a node strength of 1 or -1, meaning that these target hubs were
predicted to be regulated by three miRNAs, out of which one had an opposite expression change to the
other two (Table S1).
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Figure 1. Interaction network and miRNA target prediction analysis of downregulated miRNAs
(green) and upregulated miRNAs (red). mRNAs with less than three miRNA interactions are indicated
in light-blue colour. mRNAs targeted by three differentially expressed miRNAs are indicated in
dark-blue colour.
2.3. Gene Ontology Analysis of Predicted mRNAs
To explore biological processes modified by prediabetes, Gene Ontology (GO) analyses of all
predicted mRNAs were performed (Table S2). The result of the GO analysis clearly showed that
differentially expressed miRNA-targeted mRNAs were significantly associated with e.g., cardiac
morphogenesis, development, lipid translocation, protein autophosphorylation, connective tissue
replacement, xtracellular atrix dis ssembly, and angiogenesis-related processes (Figure 2).
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Figure 2. GO analysis (biological processes) of all miRNA target mRNAs (n= 445) highlights the effect of
prediabetes on cardiac morphogenesis, development, lipid translocation, protein autophosphorylation,
connective tissue replacement, extracellular matrix disassembly, and angiogenesis. Eighteen biological
processes with the highest fold enrichment value are presented here. *p < 0.001, vs. Control (GO
enrichment analysis with Bonferroni correction).
2.4. Validation of mRNA Targets of Predicted miRNAs
Out of the 11 mRNAs targeted by three differentially expressed miRNAs: Juxtaposed with another
zinc finger protein 1 (Jazf1); RAP2C, member of RAS oncogene family (Rap2c); Zinc finger with
KRAB and SCAN domains 1 (Zkscan1); Nuclear receptor subfamily 3 group c member 1 (Nr3c1); and
Panto nate kinase 3 (Pank3) were selected for exp imenta validation based on the GO analysis
(Table 2).
Table 2. Selected target genes indicating their miRNA connections. ↓ indicates downregulation and ↑
indicat s upregulation of the selected gene targets in the prediabetic group as compared to those in the
control group, + indicates predicted interaction between the selected target genes and the differentially
expressed miRNAs.
Target Predicted to be Regulate by
Abbreviation Name miR-141-3p ↑ miR-200a-3p ↓ miR-200c-3p ↑ miR-293-5 ↓
Nr3c1 Nuclear receptor subfamily3 group c member 1 + + +
Jazf1 Juxtaposed with another zincfinger protein 1 + + +
Rap2c RAP2C, member of RASoncogene family + + +
Zkscan1 Zinc finger with KRAB andSCAN domains 1 + + +
Pank3 Pantothenate kinase 3 + + +
To validate the resul s of small RNA-sequencing and target prediction by molecular network
analysis, the five select d mRNA targets were investigated at mRNA level with qRT-PCR. The relative
mRNA expression of Jazf1, Rap2c, and Zkscan1 significantly decreased in the prediabetic group
compared to the control group (Figure 3A,C,D). Although there was a tendency to decrease in the
expression of Nr3c1 in prediabetic animals, this difference was not statistically significant (Figure 3B).
We found that the mRNA expression of Pank3 was not affected by the treatment (Figure 3E).
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(HPRT) mRNA. Data are expressed in arbitrary units as means ± SEM. n =7, * p < 0.05, ** p < 0.01 versus 
control; unpaired Student’s t-test. 
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Overexpression of miR-208b, a member of the MyomiR family, is associated with cardiac growth and 
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Figure 3. Relative mRNA expression of (A) Juxtaposed with another zinc finger protein 1 (Jazf1);
(B) Nuclear receptor subfamily 3 group c member 1 (Nr3c1); (C) RAP2C, member of RAS oncogene
family (Rap2c); (D) Zinc finger with KRAB and SCAN domains 1 (Zkscan1); and (E) Pantothenate kinase
3 (Pank3) in prediabetic rat left ventricle samples (prediabetes) as compared to vehicle-treated controls
(control). The transcript levels were normalized to Hypoxanthine-guanine phosphoribosyltransferase
(HPRT) mRNA. Data are expressed in arbitrary units as means ± SEM. n =7, * p < 0.05, ** p < 0.01 versus
control; unpaired Student’s t-test.
3. Discussion
In the present study, we analysed cardiac miRNA expression and validated their mRNA targets in
a rat model of prediabetes induced by high-fat diet and a single low-dose streptozotocin (STZ) treatment.
For the first time in the literature, we found that prediabetes i duces cardiac miRNA expression
changes targeting Jazf1, Zkscan1, and Rap2c. Small RNA-sequencing revealed a cardiac d wnregulation
of rno-miR-200a-3p, rno-miR-293-5p, and rno-miR-208b-3p, and upregulation of rno-miR-141-3p and
rno-miR-200c-3p in prediabetes. Out of these five miRNAs, iR-200a-3p, miR-200c-3p, and miR-141-3p
belong to the miR-8 family indic ting that altered expression of the miR-8 family may play r le in
prediabetes showi g the HFpEF phenoty e. Although some of th se miRNAs have been implicated
in the athomechanism of cardiac diseases [18], their connection to th cardiac c sequences of
prediabetes has not been evidenced.
Here, w have found two upregulated miRNAs, i.e., rno-miR-141-3p and rno-miR-200c-3p,
in prediabetic rat hearts. There are some data in the literature concerning these miRNAs in cardiac
pathologies. T ese two miRNAs are tr nscribed from genes in close proximity on chromosome 4
and thus belong to the same miRNA cluster a d to th miR-8 family [17]. Ind ed, miR-141-3p and
miR-200c-3p often sh w similar expression patterns in miRNA fingerprint analysis studies [19,20].
In line with ur results, the study of Baseler showed th t cardiac miR-141 and miR-200c were
upregulated in a mouse model of type 1 diabetes mellitus (T1DM) i duced by m ltiple doses of STZ
injections [19]. Further supporting our findings, in type 2 diabetic rat hearts induced by a single
i jection of STZ, microarray analysis revealed the increased expressions of miR-200c and miR-141 [20].
These results show that miR-141-3p and miR-200c-3p may contribute to cardiac pathologies developing
in some met bolic disturbances. Previously, we have found in our high-fat, low-dose of STZ prediabetes
rat model that gene expression of β-MHC decreased in the prediabetic r t heart [8], which correlates
with the recently iscovered downreg lation of miR-208b-3p in our present study. MiR-208b is encoded
within the β-MHC gene and targets transcriptional repressors of the β-MHC [21]. Overexpression of
miR-208b, a member of the MyomiR family, is associated with cardiac growth and hypertrophy [22].
Baseler et al. showed the upre ulatio of not only miR-141 a d miR-200c but also miR-208b and
miR-295 in type 1 diabetic mouse hearts [19]. MiR-295 belongs to the same miR-290 family as miR-293,
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identified in our present study. In peripheral blood mononuclear cells of hypertensive patients with
HFpEF, a significant increase in miR-208b level was detected compared to hypertensive patients
without HFpEF [23]. These results show that miR-208b may contribute to the development of HFpEF.
In contrast to miR-208, a limited amount of data has been published on the role of miR-200a-3p and
miR-293-5p in cardiac pathologies. In the study of Sun et al., the decrease of miR-200a was observed in
tissue samples of patients with end-stage heart failure due to ischemic cardiomyopathy in comparison
with non-failing heart samples [24]. Fang L. et al. showed the upregulation of miR-200a-3p in plasma
samples of hypertrophic cardiomyopathy patients with diffuse myocardial fibrosis [25].
In the present study, we identified the altered cardiac expression of miRNAs that belong to miR-8,
miR-290 and miR-208 miRNA families in prediabetes. According to the studies of Baseler et. al. (2012)
and Saito et al. (2016), these families show differential expression in both T1DM and T2DM. However,
the total number of differentially expressed miRNA families is higher and both miR-290 and miR-208
families show upregulation in T1DM in contrast to our findings. These results suggest that prior to the
development of advanced diabetes, some of the differentially expressed miRNAs or miRNA families
appear even in prediabetes.
Here, we performed miRNA-mRNA target prediction by molecular network analysis to explore
mRNA targets of the differentially expressed miRNAs. We validated five mRNA targets out of 445
mRNAs interacting with miRNAs with altered expression. Jazf1 is a zinc finger protein and an inhibitor
of the Nuclear receptor subfamily 2, group C, member 2 (Nr2c2), which is involved in insulin resistance,
glucose and lipid metabolism, and regulation of peroxisome proliferator-activated receptor (PPAR)α,
β/δ, γ [26,27]. Interestingly, Jazf1 was found to be downregulated in pancreatic islets from T2DM
patients, and increased expression of Jazf1 was associated with higher insulin secretion and lower
hemoglobin A1c [28]. Moreover, Ho et al. (2013) suggested that decreased expression of Jazf1 may
be a consequence of hyperglycemia [29]. Thus, Jazf1 may serve as a target for future therapies of
consequences of metabolic derangements. Here we also found Rap2c (a member of the Ras-related
protein subfamily of the Ras GTPase superfamily) and Zkscan1 (encodes a member of the Kruppel
C2H2-type zinc-finger family of proteins) expression to be downregulated in the prediabetic rat heart.
Although Shaum et al. showed that Zkscan1 and Rap2c are expressed in most of the cell types of mouse
heart [30], their function remains unclear.
Although here we successfully validated the predicted mRNA targets of differentially expressed
miRNAs by qRT-PCR, there are three major limitations of our present study. 1. The direct interactions
of miRNA–mRNA were not validated experimentally, however, bioinformatics prediction is a powerful
evidence for microRNA–target interaction since mirRNAtargetTM integrates miRDB, microRNA.org
and also the experimentally validated miRTarBase database [14,31,32]. 2. Validation of the predicted
mRNA targets at protein level was out of the scope of our present study. 3. The function of the newly
identified targets was not validated either pharmacologically due to the lack of specific pharmacological
inhibitors or by genetic approaches (gene silencing, overexpression) due to the need for extensive
further experimentation which was outside the scope of this study.
4. Materials and Methods
4.1. Characterization of Prediabetes Model and Tissue Sampling
Control and prediabetic heart samples of the present study have been obtained from our previous
study Koncsos et al. (2016) [8]. Sample preparation, prediabetes model protocol, and metabolic and
cardiac parameters were described in the study of Koncsos et al. (2016) in detail [8]. Briefly, to induce
prediabetes, Long-Evans rats were fed a high-fat (40%) chow for 21 weeks and treated with a single low
dose (20 mg/kg) of STZ at week 4. To produce high-fat diet chow we added commercially available lard
(40%) to the standard chow (ssniff Spezialdiäten GmbH, Soest, Germany). Fatty acid components of
the high fat chow include: oleic acid (40.78%), palmitic acid (23.02%), stearic acid (16.00%), linoleic acid
(11.81%), octadecenoic acid isomer B (2.85%), palmitoleic acid (1.59%), and others (altogether less than
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4%). Control animals were fed a standard chow for 21 weeks and treated with the vehicle of STZ at
week 4 [8]. In the study of Koncsos et al. [8], we demonstrated that high-fat and STZ treatment induced
prediabetes that is characterized by a slight elevation in fasting blood glucose, impaired glucose and
insulin tolerance and an increase in visceral adipose tissue, leading to diastolic dysfunction and cardiac
hypertrophy. At week 21, hearts were excised under pentobarbital (60 mg/kg, i.p.) anaesthesia and
perfused with oxygenated Krebs-Henseleit solution in Langendorff mode and stored at −80◦C in
RNAlater [8].
4.2. RNA Isolation and Small RNA-Sequencing
RNAlater-preserved rat left ventricle samples (n = 6/group) were thawed on ice, then the left
ventricular tissue was placed in a 1.5 mL Eppendorf LoBind tube containing glass beads (1.7–2.1 mm
diameter, Carl Roth, Karlsruhe, Germany) and 500 µL of VRX buffer (Viogene Biotek, New Taipei City,
Taiwan, R.O.C). The Eppendorf tube was firmly attached to a SILAMAT S5 vibrator (Ivoclar Vivadent,
Schaan, Liechtenstein) in order to disrupt and homogenize the tissue for 15 s. Total RNA was extracted
using Viogene miTotal RNA Extraction Miniprep System (Viogene Biotek, New Taipei City, Taiwan,
R.O.C) according to the manufacturer’s protocol. The RNA Integrity Numbers and RNA concentration
were determined by the RNA ScreenTape system with 2200 Tapestation (Agilent Technologies, Santa
Clara, CA, USA) and the RNA HS Assay Kit with Qubit 3.0 Fluorometer (Thermo Fisher Scientific,
Waltham, MA, USA), respectively.
For small RNA library construction, the NEBNext Multiplex Small RNA Library Prep Set for
Illumina (New England Biolabs, Ipswich, MA, USA) was applied according to the manufacturer’s
protocol. The quality and quantity of the library QC was performed by using the High Sensitivity
DNA1000 ScreenTape system with 2200 Tapestation (Agilent Technologies, Santa Clara, CA, USA)
and dsDNA HS Assay Kit with Qubit 3.0 Fluorometer (Thermo Fisher Scientific, Waltham, MA,
USA), respectively. Pooled libraries were diluted to 1.8 pM for 2 × 43 bp paired-end sequencing with
75-cycle High Output v2 Kit on the NextSeq 550 Sequencing System (Illumina, San Diego, CA, USA) at
the Xenovea Ltd. according to the manufacturer’s protocol. Small RNA-sequencing datasets were
stored in the ArrayExpress database (https://www.ebi.ac.uk/arrayexpress/ with accession number:
E-MTAB-8204).
4.3. Bioinformatics Analysis of Small RNA-Sequencing Data
After adapter trimming, quality and length filtering of the raw sequencing reads by Illumina
FastQ Toolkit (version v2.2.0) only reads with an average Phred quality score over 30 and with a length
of at least 10 nt were kept for further analysis. Following quality control analysis by FastQC (version
v0.11.7), alignment of the filtered reads to Rnor_6.0 NCBI Rattus norvegicus reference genome assembly
was performed by Bowtie 2 aligner (version 2.2.1) [33]. Reads mapped to mature miRNA loci were
counted by the featureCounts software (version v1.6.2) [34] using the miRBase release 22.1 Rattus
norvegicus reference annotation [17]. EdgeR (version 3.12.1) [35] Bioconductor package was utilized for
normalization and differential expression analysis with likelihood ratio tests after applying GLM to
estimate dispersions. MiRNAs were considered to be significantly differentially expressed if the FDR
(corrected p-value according to Benjamini and Hochberg) [36] remained under 0.05.
4.4. miRNA Target Prediction and miRNA-mRNA Target Network Analysis
To predict likely targets of differentially expressed miRNAs and their combined effect on
their common targets, a miRNA–target interaction network was constructed by the miRNAtarget™
software (https://mirnatarget.com; Pharmahungary, Szeged, Hungary) as described previously [14,31].
Both predicted (miRDB version 5.0 with score > 80.0 and microRNA.org with mirSVR score < −1.2)
and experimentally validated, manually curated (miRTarBase 4.5) miRNA–target interactions were
integrated by miRNAtarget™ [37–39]. In the resulting network, miRNAs and their targets were
represented by nodes and were connected by edges of predicted interactions. After assigning positive
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or negative weights (1 or -1) to edges based on the up- or downregulation of the interacting miRNA,
respectively, node strength was calculated for each target node by summing the incoming edge weights.
Optimal network visualization was obtained by the EntOptLayout plugin (version 2.1) for the
Cytoscape (version 3.6) network analysis framework using double consideration of the main diagonal
of the adjacency matrix and sequential position and weight updates achieving a high quality layout
with negligible normalized information loss of 0.027 [40].
4.5. Gene Ontology Analysis
GO analysis using all predicted miRNA target mRNAs was conducted with the online tool of
Gene Ontology Consortium (geneontology.org). Rattus norvegicus species annotations were adopted
from the PANTHER Classification System (pantherdb.org) on 17 June 2019. GO enrichment analysis
with FDR correction was performed [41,42].
4.6. Selection of miRNA Target mRNAs for Experimental Validation
Out of the predicted 11 miRNA target hubs (i.e., mRNAs regulated by three miRNAs), two targets
had a node strength of -1 and 9 targets had a node strength of +1. All miRNA target hubs with a
node strength of -1 and those three targets with a +1 node strength and annotated with the biological
processes having the highest fold enrichment value based on GO analysis were selected for experimental
validation (Figure 2).
4.7. RNA Isolation and qRT-PCR
The total RNA was isolated from control and prediabetic left ventricle samples with Direct-zol
RNA MiniPrep according to the manufacturer’s instructions (Zymo Research Corporation Safety
Department, Irvine, CA, USA). Afterwards, cDNA was synthesized from total RNA applying Sensifast
cDNA synthesis kit (Bioline, London, UK) according to the manufacturer’s protocol. To detect the
transcript levels of Jazf1, Nr3c1, Rap2c, Zkscan1, and Pank3, quantitative real-time polymerase chain
reaction (qRT-PCR) was performed with SensiFAST SYBR No-ROX mix (SensiFASTTM SYBR® No-ROX
kit, Bioline, London, UK) on a Light Cycler® 480 (Roche, Applied Science, Penzberg, Upper Bavaria,
Germany). Hypoxanthine-guanine phosphoribosyltransferase (HPRT) was used as a reference gene.
Primer pairs for Jazf1, Nr3c1, Rap2c, Zkscan1, Pank3, and HPRT were designed against sequences of
intron-spanning exons by Primer-BLAST software (http://www.ncbi.nlm.nih.gov/tools/primer-blast/)
and tested to avoid primer dimers, non-specific amplification, and self-priming by this software
(Table 3).
Table 3. Primer properties used in qRT-PCR for the determination of transcript levels. Nr3c1, nuclear
receptor subfamily 3 group c member 1; Jazf1, Jazf zinc finger protein 1; Rap2c, member of RAS oncogene
family; Zkscan1, zinc finger with KRAB and SCAN domains 1; Pank3, Pantothenate kinase 3; HPRT,
Hypoxanthine-guanine phosphoribosyltransferase; and bp, base pair.
Target Accession Number Forward Primer Reverse Primer Product Size (bp)
Nr3c1 NM_012576.2 AGGCGATACCAGGCTTCAGA TCAGGAGCAAAGCAGAGCAG 142
Jazf1 XM_001065610.6 CCAACAGGCAGCGAGTATGA AGGCTTCTCTTCCCCTCCAT 138
Rap2c NM_001106950.2 GGCCATACCGAGCAGATAAAAAC TGGATCTGGAGGGCCAAAGA 164
Zkscan1 NM_001025760.1 GGAGTCCTCAAGCTTCGACC GATCTTCACCATTGCCTGGGA 193
Pank3 NM_001108272.2 TGGGCTGTGGCATCTAGTTTT AACAGCACACATTCGAGCCA 135
HPRT NM_012583.2 GTCCTGTTGATGTGGCCAGT TGCAAATCAAAAGGGACGCA 144
Cycle conditions were the following: 95 ◦C for 2 min, followed by 40 cycles of 95 ◦C for 5 s, 61 ◦C
for 10 s, then 72 ◦C for 20 s. Every reaction was implemented in duplicate to ensure the reliability of
single values. Measurements included dissociation curve analysis and amplicon length verification on
2% agarose gel to ensure amplification specificity. 2−∆∆Cp methods were used to determine the relative
gene expression ratio.
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4.8. Statistical Analysis
Unpaired Student’s t-test was performed to compare the data of qRT-PCR analysis with GraphPad
Prism 8.0.1. (GraphPad Software Inc.; San Diego, CA, USA). Data are shown as mean ± standard error
of mean (SEM), p < 0.05 was considered statistically significant.
5. Conclusions
In conclusion, our present results show that mild prediabetes induces miRNA expression changes
leading to altered gene expression of Jazf1, Zkscan1, and Rap2c, which may contribute to the diastolic
dysfunction and may serve as potential drug targets. However, the mechanistic role of the identified
molecular targets in prediabetes-induced HFpEF should be further investigated.
Supplementary Materials: The following are available online at http://www.mdpi.com/1422-0067/21/6/2128/s1,
Table S1: Predicted miRNA-target interaction list, Table S2: Detailed results of Gene Ontology enrichment analysis
of the predicted targets of differentially expressed miRNAs.
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